Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Common Equity (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Common Equity data on record, last reported at -$108.5 million in Q4 2025.

  • For Q4 2025, Common Equity fell 138.31% year-over-year to -$108.5 million; the TTM value through Dec 2025 reached -$108.5 million, down 138.31%, while the annual FY2025 figure was -$108.5 million, 138.31% down from the prior year.
  • Common Equity reached -$108.5 million in Q4 2025 per FHTX's latest filing, down from -$89.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $125.2 million in Q1 2021 and bottomed at -$108.5 million in Q4 2025.
  • Average Common Equity over 5 years is -$8.9 million, with a median of -$26.4 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 223.67% in 2021, then plummeted 69019.64% in 2023.
  • A 5-year view of Common Equity shows it stood at $96.9 million in 2021, then plummeted by 99.88% to $112000.0 in 2022, then tumbled by 69019.64% to -$77.2 million in 2023, then surged by 41.02% to -$45.5 million in 2024, then crashed by 138.31% to -$108.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$108.5 million in Q4 2025, -$89.7 million in Q3 2025, and -$76.7 million in Q2 2025.